Atlas Trials

NewAmsterdam Pharma

19 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch NewAmsterdam Pharma

RecordFirmDate
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (NCT07219602)NewAmsterdam Pharma2025-12-11
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers (NCT06982508)NewAmsterdam Pharma2025-09-09
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels (NCT06496243)NewAmsterdam Pharma2024-12-02
A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects (NCT06547359)NewAmsterdam Pharma2024-10-01
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque (NCT06305559)NewAmsterdam Pharma2024-05-16
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies (NCT06005597)NewAmsterdam Pharma2024-03-01
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib (NCT06250205)NewAmsterdam Pharma2024-02-05
Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe (NCT06050291)NewAmsterdam Pharma2024-01-20
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism (NCT05972278)NewAmsterdam Pharma2023-12-01
A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin (NCT06081166)NewAmsterdam Pharma2023-11-11
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. (NCT05425745)NewAmsterdam Pharma2022-07-25
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. (NCT05421078)NewAmsterdam Pharma2022-06-27
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy (NCT05266586)NewAmsterdam Pharma2022-03-09
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease (NCT05161715)NewAmsterdam Pharma2022-01-12
Randomized Study of Obicetrapib in Combination With Ezetimibe (NCT04770389)NewAmsterdam Pharma2021-02-23
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (NCT04753606)NewAmsterdam Pharma2021-02-18

Track NewAmsterdam Pharma automatically

Every clearance here is in the API, with alerts when new ones post.